By understanding potential material change, the impact on patient safety can be understood and mitigated.
Andrew Feilden
Advertisement
Andrew Feilden is the European E&L strategic director for Element.
Articles by Andrew Feilden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5
